View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSolgenics 과거 순이익 실적과거 기준 점검 0/6Solgenics의 연간 평균 수익은 5.2%였으며, Oil and Gas 산업의 수익은 연간 9.5% 증가했습니다.핵심 정보5.20%순이익 성장률14.20%주당순이익(EPS) 성장률Oil and Gas 산업 성장률37.29%매출 성장률n/a자기자본이익률-15.78%순이익률n/a최근 순이익 업데이트30 Jun 2022최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 04Solgenics Proposes DelistingSolgenics Limited announced that it will shortly be posting a circular to shareholders in connection with a proposal for the cancellation of admission of the ordinary shares of no par value in the Company to trading on AIM, pursuant to Rule 41 of the AIM Rules for Companies. The Directors have conducted a review of the benefits and drawbacks to the Company and its shareholders in retaining its quotation on AIM, and believe that Cancellation is in the best interest of the Company and its shareholders as a whole. In reaching this conclusion, the Directors have considered the following key factors: the continued listing on AIM is unlikely to provide the Company with significantly wider or more cost-effective access to capital than the funding options it already has from majority shareholders in the near to mid-term; with a market capitalisation of £3.26 million the Directors have concluded that the most likely source of future funds will be through private capital; the considerable cost, management time and legal and regulatory burden associated with maintaining the Company's admission to trading on AIM are disproportionate to the benefits to the Company; there are negative operational influences on the business which come about directly as a result of being quoted, something which is accentuated by operating in an industry where the vast majority of the Company's peers are privately owned. The Company's peers also have far greater insight into its strategy, operational activities and future plans than the Company has into theirs, a factor which reduces the Company's relative competitiveness; the Company's market capitalisation and lack of liquidity in the Ordinary Shares have impacted certain of the potential advantages to having the shares admitted to trading on AIM. Accordingly, the Directors believe that it is in the best interests of the Company and its shareholders as a whole to cancel the admission of the Company's Ordinary Shares to trading on AIM. The Board does not consider that any potential benefits to the Company or Shareholders from retaining the AIM Admission are sufficient to justify the associated costs. In accordance with Rule 41 of the AIM Rules, the Company's Nominated Adviser has notified the London Stock Exchange of the proposed Cancellation. Pursuant to AIM Rule 41, the Cancellation can only be effected by the Company after securing a resolution of Shareholders in a general meeting passed by a requisite majority, being not less than 75 per cent. of the votes cast by Shareholders (in person or by proxy). The Directors have indicated they will vote in favour of the Cancellation. Under the AIM Rules, the Cancellation can only take place after the expiry of a period of twenty Business Days from the date on which notice of the Cancellation is given. In addition, a period of at least five Business Days following the Shareholder approval of the Cancellation is required before the Cancellation may be put into effect. Accordingly, if the Resolution to cancel the Admission is approved, the last day of dealings in the Ordinary Shares on AIM is expected to be 6 June 2023, and the Cancellation is expected to become effective at 7.00 a.m. on 7 June 2023.Recent Insider Transactions • Jan 19Non-Executive Director recently bought €63k worth of stockOn the 16th of January, Scott Fletcher bought around 7m shares on-market at roughly €0.0087 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €145k more in shares than they have sold in the last 12 months.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Scott Fletcher was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • May 16Non-Executive Director recently bought €54k worth of stockOn the 9th of May, Scott Fletcher bought around 5m shares on-market at roughly €0.011 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Scott Fletcher was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Apr 09Non-Executive Director recently bought €409k worth of stockOn the 6th of April, Scott Fletcher bought around 10m shares on-market at roughly €0.041 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €9.8m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Nov 20Insider recently bought €9.2m worth of stockOn the 16th of November, Scott Fletcher bought around 2m shares on-market at roughly €4.20 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.매출 및 비용 세부 내역Solgenics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:9NE 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 220-22031 Mar 220-22031 Dec 210-22030 Jun 210-22031 Mar 210-22031 Dec 200-32030 Sep 200-32030 Jun 200-22031 Mar 200-22031 Dec 190-22030 Sep 190-22030 Jun 190-22031 Mar 190-32031 Dec 180-33030 Sep 180-33030 Jun 180-32031 Mar 180-32031 Dec 170-21030 Sep 170-21030 Jun 170-31031 Mar 170-32031 Dec 160-32030 Sep 160-22030 Jun 160-12031 Mar 160-22031 Dec 150-23030 Sep 150-194030 Jun 150-375031 Mar 150-375031 Dec 140-386030 Sep 140-226030 Jun 140-66031 Mar 140-77031 Dec 130-77030 Sep 130-88030 Jun 130-88031 Mar 130-88031 Dec 120-99030 Sep 120-1090양질의 수익: 9NE 은(는) 현재 수익성이 없습니다.이익 마진 증가: 9NE는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 9NE는 수익성이 없지만 지난 5년 동안 연평균 5.2%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 9NE의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 9NE은 수익성이 없어 지난 해 수익 성장률을 Oil and Gas 업계(7.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 9NE는 현재 수익성이 없으므로 자본 수익률이 음수(-15.78%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YEnergy 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/06/29 19:02종가2023/06/06 00:00수익2022/06/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Solgenics Limited는 3명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Alexander BrooksCanaccord GenuityMartin PottsCavendishAndrey LitvinEdison Investment Research
공시 • May 04Solgenics Proposes DelistingSolgenics Limited announced that it will shortly be posting a circular to shareholders in connection with a proposal for the cancellation of admission of the ordinary shares of no par value in the Company to trading on AIM, pursuant to Rule 41 of the AIM Rules for Companies. The Directors have conducted a review of the benefits and drawbacks to the Company and its shareholders in retaining its quotation on AIM, and believe that Cancellation is in the best interest of the Company and its shareholders as a whole. In reaching this conclusion, the Directors have considered the following key factors: the continued listing on AIM is unlikely to provide the Company with significantly wider or more cost-effective access to capital than the funding options it already has from majority shareholders in the near to mid-term; with a market capitalisation of £3.26 million the Directors have concluded that the most likely source of future funds will be through private capital; the considerable cost, management time and legal and regulatory burden associated with maintaining the Company's admission to trading on AIM are disproportionate to the benefits to the Company; there are negative operational influences on the business which come about directly as a result of being quoted, something which is accentuated by operating in an industry where the vast majority of the Company's peers are privately owned. The Company's peers also have far greater insight into its strategy, operational activities and future plans than the Company has into theirs, a factor which reduces the Company's relative competitiveness; the Company's market capitalisation and lack of liquidity in the Ordinary Shares have impacted certain of the potential advantages to having the shares admitted to trading on AIM. Accordingly, the Directors believe that it is in the best interests of the Company and its shareholders as a whole to cancel the admission of the Company's Ordinary Shares to trading on AIM. The Board does not consider that any potential benefits to the Company or Shareholders from retaining the AIM Admission are sufficient to justify the associated costs. In accordance with Rule 41 of the AIM Rules, the Company's Nominated Adviser has notified the London Stock Exchange of the proposed Cancellation. Pursuant to AIM Rule 41, the Cancellation can only be effected by the Company after securing a resolution of Shareholders in a general meeting passed by a requisite majority, being not less than 75 per cent. of the votes cast by Shareholders (in person or by proxy). The Directors have indicated they will vote in favour of the Cancellation. Under the AIM Rules, the Cancellation can only take place after the expiry of a period of twenty Business Days from the date on which notice of the Cancellation is given. In addition, a period of at least five Business Days following the Shareholder approval of the Cancellation is required before the Cancellation may be put into effect. Accordingly, if the Resolution to cancel the Admission is approved, the last day of dealings in the Ordinary Shares on AIM is expected to be 6 June 2023, and the Cancellation is expected to become effective at 7.00 a.m. on 7 June 2023.
Recent Insider Transactions • Jan 19Non-Executive Director recently bought €63k worth of stockOn the 16th of January, Scott Fletcher bought around 7m shares on-market at roughly €0.0087 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €145k more in shares than they have sold in the last 12 months.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Scott Fletcher was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • May 16Non-Executive Director recently bought €54k worth of stockOn the 9th of May, Scott Fletcher bought around 5m shares on-market at roughly €0.011 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Scott Fletcher was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Apr 09Non-Executive Director recently bought €409k worth of stockOn the 6th of April, Scott Fletcher bought around 10m shares on-market at roughly €0.041 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €9.8m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Nov 20Insider recently bought €9.2m worth of stockOn the 16th of November, Scott Fletcher bought around 2m shares on-market at roughly €4.20 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.